Abbott Laboratories reported $44.3 billion in revenue and a 52nd consecutive dividend increase — the kind of headline that signals a diversified compounder. But the 10-K's segment footnotes reveal that Medical Devices generates 61% of segment operating income, the $23 billion Exact Sciences acquisition targets the lowest-return division, and 1,760 infant formula lawsuits carry zero reserves. Here's what the filing reveals about the real risk-reward behind a 33.6× P/E.
Edwards Lifesciences reported Q4 GAAP EPS of $0.11 — missing consensus by 82%. But the same filing reveals 60.5% segment operating margins, among the highest in medtech. The $534 million in litigation, impairments, and restructuring charges that crushed reported earnings mask an adjusted operating margin of 29.4%. The real question isn't whether Edwards is profitable — it's whether the TMTT franchise ($551M, +56.4%) can reach contribution-positive scale before TAVR decelerates, while a $920.8 million tax contingency looms over the fortress balance sheet.
Medline Inc. grew revenue 11.5% to $28.4 billion — the fastest among its med-surg peers. But the 10-K reveals that $2.9 billion in new revenue produced just $67 million in incremental operating income, a 2.3% capture rate below the company's own cost of debt. With ROIC at 5.96% versus a 6.50% cost of debt, a Q4 gross margin cliff to 24.6%, and a potential $11 billion Tax Receivable Agreement owed to PE sponsors, the filing documents a capital structure that demands more than operations can deliver.
Boston Scientific has written off $9.9 billion in cumulative goodwill impairments — 35% of every dollar ever booked. Yet in FY2025, the serial acquirer's ROIC crossed 9.1% for the first time in 20 quarters. Then BSX announced $14.5 billion for Penumbra, which will spike leverage from 1.95× to ~4.1× net debt/EBITDA — landing 0.65× below the covenant ceiling. The 10-K reveals a company at a binary inflection: the acquisition lifecycle model either compounds from here, or a history of goodwill destruction repeats at unprecedented scale.
Medtronic delivered Q3 FY2026 revenue of $9.02 billion — its highest growth rate in 10 quarters at 8.7% year-over-year — with non-GAAP EPS of $1.36 beating consensus by $0.02. The stock fell 3.2% anyway. The 10-Q filing reveals why: $306-356M in MiniMed separation costs are front-loaded into the income statement, a $1.146B antitrust verdict went unmentioned in the press release, and Medical Surgical's $19.8B goodwill sits on a cushion of just 12%. Cardiovascular acceleration — up 13.8% with PFA capturing 80% of the EP market — is the real story, but the separation repricing makes it harder to see.
Stryker just posted its fourth consecutive year of double-digit revenue growth, crossing $25 billion. Operating margins expanded 314 basis points. But the 10-K reveals that $807 million of that expansion is an impairment swing — not operational efficiency. The annual cost of being a serial acquirer totals $1,659 million, exceeding Stryker's entire R&D budget, and all of it is excluded from the adjusted earnings that underpin a 41x multiple. Meanwhile, 68% of pre-tax income flows through international operations generating just 24% of revenue, and the German tax authority has assessed $754 million.
Intuitive Surgical generates 3x the returns on capital of Medtronic and Stryker. DuPont decomposition reveals ISRG wins on both NOPAT margin (25.6% vs 15%) AND capital turnover (0.84x vs 0.49x) — a rare double advantage. The counter-intuitive finding: high stock compensation actually understates their operating efficiency.
Boston Scientific has 69% gross margins. Abbott has 56%. Yet Abbott's ROIC is 2.6x higher. This paradox reveals something fundamental about capital efficiency in medical devices—and why screening for 'high margin' stocks can lead you astray.